The North American mRNA synthesis and manufacturing market demonstrates consistent growth from 2020, with revenues surging sharply during the peak of the COVID-19 pandemic and maintaining an upward trajectory due to advancements in vaccine and therapeutics R&D. The market is projected to reach 10,100 Million USD by 2025 and expand to 27,800 Million USD by 2035, reflecting persistent innovation and increasing therapeutic approvals.
Read More - https://bussinessinsights.com/research-report/north-america-mrna-synthesis-and-manufacturing-market
Vaccines continue to lead mRNA applications, reflecting the legacy of COVID-19 demand and emerging RSV/influenza mRNA vaccines. Cancer immunotherapy is the second-largest application, benefiting from robust clinical pipelines and strategic partnerships. Growing interest is seen in protein replacement therapy, gene editing, and treatments for rare diseases, driving diversified development efforts and broader market penetration among biotech innovators.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-mrna-synthesis-and-manufacturing-market
Who are the key players in North America mRNA Synthesis & Manufacturing Market industry?
The top 5 players are Moderna Inc., Pfizer Inc., Thermo Fisher Scientific, BioNTech SE, and Ginkgo Bioworks. These companies lead through advanced technology platforms, extensive R&D, strategic partnerships, and robust manufacturing capabilities driving innovation in mRNA therapeutics and vaccine development across North America.
What is the North America mRNA Synthesis & Manufacturing Market growth?
The North America mRNA Synthesis & Manufacturing Market has shown significant growth, particularly after the COVID-19 pandemic. Moderna and Pfizer led the surge, bolstered by increased demand for mRNA-based vaccines and investments in expanding manufacturing capacities, contributing to a double-digit CAGR from 2022 to 2024.
Which segment accounted for the largest North America mRNA Synthesis & Manufacturing Market share?
The vaccine application segment accounted for the largest market share, driven by widespread adoption of mRNA vaccines for COVID-19, influenza, and emerging infectious diseases. This dominance is due to the rapid development, regulatory approvals, and large-scale commercialization efforts by companies such as Pfizer and Moderna.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com